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CHAPTER -I
INTRODUCTION
1. INTRODUCTION
Oral route is the most preferred for administration of drugs owing to its known
advantage of better patient compliance. Drugs administered by oral route should dissolve in
gastric and intestinal fluid before they permeate through the membrane of GI tract and enter
into systemic circulation. So solubility is a prerequisite for absorption of drugs.
Poorly soluble drugs poses dissolution rate limited absorption. In other words in-
vitro dissolution is the index of in-vivo absorption of poorly soluble drugs. Enhancement of
solubility  of  poorly  soluble  drugs  improves  dissolution  and  absorption  with  improved
bioavailability  and  better  therapeutic  action  and  patient  compliance.  A  number  of
methodologies adopted to improve solubilization of poorly water-soluble drugs further to
improve its bioavailability. The techniques generally employed for solubilization of drugs
include micronization, chemical modification, pH adjustment, solid dispersion complex, co-
solvency, micellar solubilization, hydrotropy etc.
                     Itraconazole is an orally active triazole antifungal agent1. It demonstrates
broad  spectrum  of  antifungal  activity  against  a  number  of  fungal  species  including
dermatophytes.  Malasesia fur-fur,  Candida species, Aspergillus species, and histoplasma,
capsulatum var, capsulatum.2 It acts by selective distruption of cytochrome P-450 mediated
ergosterol synthesis in fungal membrane and there by leads to cell death.3 Itraconazole is an
extremely weak base (pKa = 3.7) which is virtually unionized at physiological pH.4,5 The
drug is poorly soluble and so its efficacy is severely  limited. Absorption is enhanced by
concurrent administration of food.6 similarly ketoconazole absorption is markedly inhibited
by  agents  which  increases  gastric  pH.7 Improvement  of  the  oral  bioavailability  of
Itraconazole has been problematic. However concentration of Itraconazole in serum may be
variable  and  suboptimal,  there  by  potentially  compromising  therapy.  Indeed  treatment
failures have been associated with low concentration of Itraconazole in blood 8 because of
the hydrophobic structure of all azoles. This may adversely affect concentration in blood
when given orally.  Therefore,  enhanced  dissolution of  itraconazole  will  be  beneficial  to
improve its absorption and bioavailability following oral administration.
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                    Complexation is one of the approaches followed to improve solubility of
poorly  soluble  drugs.  β  -Cyclodextrin  a  product  of  enzymatic  degradation  of  starch  by
Bacillusmacerans, has  been  used  in  pharmaceutical  field  to  improve  the  solubility  of
hydrophobic compounds. β -Cyclodextrin interact with hydrophobic molecules and form a
non-  covalent  inclusion  complex  that  lowers  the  chemical  potency  of  the  molecule  in
solution and thus enhances the solubility of the molecule. Pharmaceutical modification of
drug molecule by inclusion complex with cyclodextrins has been extensively developed to
improve  solubility,  dissolution  rate,  chemical  stability,  absorption  and  bioavailability  of
poorly water soluble drugs and reduces side effects and toxicity of drugs.9-17
                   βs-cyclodextrins has been used to form inclusion complex with itraconazole.18
Pyroxicam and miconazole, 19,  20 ibuprofen  21 and showed improved dissolution of  those
drugs.  In  a  previous  study22 an  improved  dissolution  at  pH  1.4  and  bioavailability  of
Itraconazole β-cyclodextrin inclusion complex prepared by supercritical carbon did-oxide
method has been reported in animal model. It has also been documented that absorption of
Itraconazole is enhanced by concurrent administration of food.6 the gastric pH increases in
the presence of food and influence the absorption and bioavailability of Itraconazole. Upon
reviewing the literature, the influence of varied pH conditions in acidic environment of the
stomach on the dissolution and bioavailability of Itraconazole β-cyclodextrin complex is
lacking and therefore the present study was attempted to investigate the same. Itraconazole
β-cyclodextrin  inclusion  complex  was  prepared  by  co  precipitation  method  in  different
concentrations  of  β-cyclodextrins  and  evaluated  for  in-vitro  dissolution  and  in-vivo
bioavailability in comparison with physical mixture and pure drug. The study may offer
scope  for  understanding  the  bioavailability  behaviour  of  Itraconazole  in  varied  pH
conditions of the stomach and its therapeutic efficacy.
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CHAPTER - II
REVIEW OF
LITERATURE
2.  REVIEW OF LITERATURE
The therapeutic effectiveness of a drug depends up on the bioavailability of drug
molecule. Solubility is one of the parameter to achieve desired therapeutic concentration
of drug.  The term ‘solubility’ is defined as maximum amount of solute that can be
dissolved in a given amount of solvent. In the Biopharmaceutical Classification System
(BCS  -  II)  drugs  with  poor  aqueous  solubility  are  poorly  bioavailable.  It  has  been
estimated that 40% of the new chemical entities currently being discovered are of poor
water-solubility.23
Many poorly soluble drugs are either basic or acidic in character and thus exhibit
structural components which can be protonated or deprotonated, respectively. In the GIT,
the local pH environment varies from the upper small intestine to the distal colon, the
drug absorption depending upon whether the molecule is predominantly acidic or basic.
For example, in a predominantly acidic environment, a weak acidic will remain unionised
and thus be absorbed via the passive trans-cellular route. The pH of the buffer media can
strongly influence the solubility of such compounds, and thus the required permeability
values are achieved.  To develop dosage form, oral route of drug delivery is the simple
and most convenient  way of  administration of all  the drugs,  because of more patient
compliance, less side effects and more stable. There are many techniques to improve the
solubility of  poorly soluble  drugs,  such  as  solubilisation,  chemical  modification,  size
reduction, formation of inclusion complexes. 24
Noyes-Whitney equation: 
Illustrates how the dissolution rate of even very poorly soluble compounds might
be improved to minimize the limitations to oral bioavailability:
   dc/dt    =    AD(Cs- c)/h
3
Where
                        dC/ dt is the rate of dissolution,
                                    A is the surface area available for dissolution,
                                    D is the diffusion coefficient of the compound,
                                    Cs is the solubility of the compound in the dissolution medium,
                                    C is the concentration of drug in the medium at time t .
                                    H is the thickness of the diffusion layer.
sTechniques for solubility enhancement 
There are various techniques available to improve the solubility of hydrophobic
drugs. Some traditional and novel approaches to improve the solubility are: 
1. Particle Size Reduction 
2. Solid Dispersion 
3. Nanosuspension 
4. Supercritical Fluid Technology 
5. Cryogenic Technology 
6. Inclusion Complex Formation Techniques 
7. Floating Granules
 β-Cyclodextrins: 
Cyclodextrins  are  cyclic  oligosaccharides  containing  at  least  6  D-(+)
glucopyranose  units  attached  by  α-(1,  4)  Glucosidic  bonds.  (CDs),  They  were  first
discovered in 1891,25 various approaches that have been used to improve the solubility
and  dissolution  rate  of  drugs,  complexation  with  cyclodextrins  is  one  of  the  most
promising ones, which enhance their solubility, dissolution rate, chemical stability and
bioavailability and reduce their side effects and toxicity. Preparation of solid inclusion
complexes between cyclodextrins and various drugs includes kneading, co-evaporation,
sealed-heating,  co-grinding,  spray-drying  and  freeze-drying.26  the  use  of  supercritical
carbon dioxide (sc co2) has been recently proposed for the preparation of various drug-
cyclodextrin inclusion complexes for enhanced solubility and dissolution rate.
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Cyclodextrins are able to form solid inclusion complexes (host–guest complexes)
with  a  very  wide  range  of  solid,  liquid  and  gaseous  compounds  by  a  molecular
complexation.25 In these complexes,  a guest molecule is held within the cavity of the
cyclodextrin host molecule. Complex formation is a dimensional fit between host cavity
and  guest  molecule.27 The  lipophilic  cavity  of  cyclodextrin  molecules  provides  a
microenvironment into which appropriately sized non-polar moieties can enter to form
inclusion complexes.28 No covalent bonds are broken or formed during formation of the
inclusion  complex.29 The  main  driving  force  of  complex  formation  is  the  release  of
enthalpy-rich water molecules from the cavity. Water molecules are displaced by more
hydrophobic guest molecules present in the solution to attain an apolar–apolar association
and decrease of cyclodextrin ring strain resulting in a more stable lower energy state.30
5
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o
Category Example of carriers
1.
Polymers
Polyvinylpyrrolidone, Polyvinylpolypyrrolidone,
Polyvinyl alcohol, Polyethylene glycols, 
Hydroxypropyl methylcellulose, Hydroxypropyl 
cellulose, Poly (2-hydroxyethylmethacrylate), 
Methacrylic copolymers (Eudragit® S100 sodium salts 
and Eudragit® L100 sodium salts).
2. Superdisintegrants
Sodium starch glycolate, Croscarmellose sodium,
Cross-linked polyvinylpyrrolidone, Cross-linked 
alginic acid,
Gellan gum, Xanthan gum, Calcium silicate.
3. Cyclodextrins β -Cyclodextrins, Hydroxypropyl-β-cyclodextrins.
4. Carbohydrates
Lactose, Soluble starch, Sorbitol, Mannitol,
β-(1-4)-2-amino-2-deoxy-D-glucose (Chitosan),
Maltose, Galactose, Xylitol, Galactomannan, British 
gum, Amylodextrin.
5. Surfactants
Poloxamers (Lutrol® F 127, Lutrol® F 68), 
Polyglycolized glyceride (Labrasol), Polyoxyethylene 
sorbitan monoesters (Tweens), Sorbitan esters (Spans), 
Polyoxyethylene stearates, Poly (beta-benzyl-L-
aspartate) -b- poly (ethylene oxide), Poly
(caprolactone) -b- poly (ethylene oxide).
6. Hydrotropes  Urea, Nicotinamide, Sodium benzoate, Sodium 
salicylate, Sodium acetate, Sodium-o-hydroxy 
benzoate, Sodium-p-hydroxy benzoate, Sodium citrate.
7. Polyglycolized
glycerides Gelucire 44/14, Gelucire 50/13, Gelucire 62/05
8. Acids Citric acid, Succinic acid, Phosphoric acid.
9. Dendrimers Starburst® polyamidoamine (PAMAM).
Table 1:  Different types of polymers/ carriers 
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 Types of inclusion complexes
1. Physical blending method
2.  Kneading method
3.  Co-precipitation technique
4.   Solution/solvent evaporation method
5.  Neutralization precipitation method
6.  Milling/Co-grinding technique
7.  Atomization spray drying method
8.  Lyophilization/ spray drying method
9.  Microwave irradiation method 
10. Supercritical anti- solvent technique
1. Physical blending method:
A solid physical  mixture of drug and CDs are prepared simply by mechanical
trituration. In laboratory scale CDs and drug are mixed together thoroughly by trituration
in a mortar and passes through appropriate sieve to get the desired particle size in the
final product. In industry scale, the preparation of physical mixtures is based on extensive
blending of the drug with CDs in a rapid mass granulator usually for 30 minutes. These
powdered physical mixtures are then stored in the room at controlled temperatures and
humidity conditions. 31
2. Kneading method:
This method is based on impregnating the CDs with little amount of water or
hydro alcoholic solutions to converted into a paste. The drug is then added to the above
paste and kneaded for a specified time. The kneaded mixture is then dried and passed
through sieve if required32. (Parik et al.)33 have reported the dissolution enhancement of
nimesulide using complexation method. In laboratory scale kneading can be achieved by
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using a mortar and Pestel.34-36  In large scale the kneading can be done by utilizing the
extruders  and other  machines.  This  is  the  most  common and simple  method used  to
prepare the inclusion complexes and it presents very low cost of production.
3.  Co-precipitation technique:
This method involves the co-precipitation of drug and CDs in a complex. In this
method, required amount of drug is added to the solution of CDs. The system is kept
under magnetic agitation with controlled process parameters and the content is protected
from the light. The formed precipitate is separated by vacuum filtration and dried at room
temperature in order to avoid the loss of the structure water from the inclusion complex.
Moyano et.al.37 studied the solid-state characterization and dissolution characteristics of
gliclazide-bete-cyclodextrin inclusion complexes. 
This  technique  leaves  a  drug-CD  solution  in  very  close  conditions  to  the
saturation and through abrupt changes of temperature with addition of organic solvents. It
is obtained to the precipitation of the material forming inclusion complex. The powders
are obtained by rotation or filtration with heat while stirring the solution.38 However, due
to low yield, risk of using organic solvents, and longer time required for the preparation
in larger scale, this method is attaining little attraction in the industrial scale.39
4. Solution/solvent evaporation method:
This  method  involves  dissolving  of  the  drug  and  CDs  separately  in  to  two
mutually miscible solvents, mixing of both solutions to get molecular dispersion of drug
and complexing agents and finally evaporating the solvent under vacuum to obtain solid
powdered inclusion compound. Generally, the aqueous solution of CDs is simply added
to  the  alcoholic  solution  of  drugs.  The  resulting mixture  is  stirred  for  24  hours  and
evaporated under vaccum at 45 ºc. The dried mass was pulverized and passed through a
60-mess sieve. This method is quite simple and economic both on laboratory and large
scale production and is considered alternative to the spray drying technique.31
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5. Supercritical anti-solvent technique:
 In the supercritical fluid anti-solvent technique, carbon dioxide is used as anti-
solvent for the solute but as a solvent with respect to the organic solvent. The use of
supercritical carbon dioxide is advantageous as its low critical temperature and pressure
makes it attractive for processing heat-labile pharmaceuticals. It is also non-toxic, non-
flammable,  in-expensive and is  much easier  to  remove from the polymeric materials.
Supercritical  particle  generation  processes  are  new and  efficient  route  for  improving
bioavailability of pharmaceutically active compounds.40 in  addition,  supercritical  fluid
processes were recently proposed as a new alternative method for the preparation of drug
cyclodextrin complexes. 
In  this technique,  first,  drug and CD are dissolved in a good solvent then the
solution is fed into a pressure vessel under supercritical conditions, through a nozzle (i.e.
sprayed  into  supercritical  fluid  anti-solvent).  When  the  solution  is  sprayed  in  to
supercritical fluid anti-solvent, the anti-solvent rapidly diffuses into that liquid solvent as
the  carrier  liquid  solvent  counter  diffuses  into  the  anti-solvent.  Because  of  the
supercritical fluid expanded solvent has lower solvent power than the pure solvent, the
mixture becomes supersaturated resulting in the precipitation of the solute and the solvent
is carried away with the supercritical fluid flow.41,42
Cyclodextrins as permeation enhancers:
CDs can also be used as membrane permeability enhancer and stabilizing agents
43,  44
.  The  permeability  of  the  poorly  soluble  drugs  through  biological  membrane  is
enhanced by the presence of cyclodextrins. Masson45 these acts as permeation enhancers
by  carrying  the  drug  through  the  aqueous  barrier  which  exists  before  the  lipophilic
surface  of  biological  membranes.46  this  can  also  be  achieved  through  the  double
characteristics of the CDs, thus present character much lipophilic as hydrophilic. CDs can
also be used as nasal permeation enhancers acting by interaction with nasal epithelium by
modifying tight junction & lipid and protein content of the membrane, which enhances
the permeation of the membrane.47 CDs, can also be utilized as permeation enhancer in
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pulmonary drug delivery systems.  Rifampicin is  a  so-  called concentration-dependent
antibiotic,  the  rate  and  extent  of  bacterial  kill  is  related  to  the  attainment  of  high
maximum concentration relative to the minimal inhibitory concentration. The rifampicin-
CD inclusion compound can improve the lung transport of drug when nebulized with
compatible pulmonary deposition and achieve required concentration of drug in bronchi-
alveolar epithelium lining-fluid when administered as aerosolized 48-51
 Advantages of β-cyclodextrins:
CDs have mainly been used as complexing agents to increase the aqueous solubility
of  poorly  water-soluble  drugs  and  to  increase  their  bioavailability  and  stability.  In
addition, CDs have been used to reduce or prevent gastrointestinal or ocular irritation,
reduces unpleasant smells or tastes, prevent drug - drug or drug-additive interactions, or
even to convert oils and liquid drugs into microcrystalline or amorphous powders.
1. Enhancement of solubility: CDs increase the aqueous solubility of many poorly
soluble  drugs  by  forming  inclusion  complexes  with  their  polar  molecules  or
functional groups. And observe  water-soluble CD drug complex.52
2. Enhancement of bioavailability: Poorly bioavailable dugs are complexed with
CD, dissolution rate and, absorption is enhanced. Reducing the hydrophobicity of
drugs  by  CD  complexation  also  improves  their  per-cutaneous  or  rectal
absorption.53
3. Improvement of stability: CD complexes are improving the chemical, physical
and thermal stability of drugs.54
4. Reduction of irritation: Drug substances that irritate the stomach, skin or eye
can  be  encapsulated  within  a  CD  cavity  to  reduce  their  irritancy.  Inclusion
complexation  with  CDs  reduces  the  local  concentration  of  the  free  drug.  So
reduce the irritation. 
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5. Prevention of incompatibility: Drugs are often incompatible with each other or
with other inactive ingredients present in a formulation. Encapsulating one of the
incompatible  ingredients  within  a  CD  molecule  prevent  drug-drug  or  drug-
additive interaction.55
6. Odour and taste masking: Unpleasant odour and bitter taste of drugs can be
masked by complexation with CDs. 
7. Material handling benefits: Substances that are oils/liquids at room temperature
can  be  difficult  to  handle  and  formulate  into  stable  solid  dosage  forms.  By
Complexation with  CDs may convert  such substances  into  microcrystalline or
amorphous powders which can be conveniently.56
Table 2:  Analytic methods for characterization of solid forms
S.no                 Methods                              Significance
1.
Thermal analysis
a. Cooling Curve Method
b. Thaw Melt Method
c. Thermo  microscopic
Method
d. Zone Melting Method
e. DSC Studies
f. DTA Studies
To  study  the  morphology  and  degree  of
crystallinity.
To find out the interaction between drug and
carrier and formation of inclusion complex. 
2 X-ray Powder Diffraction Studies To  find  out  the  crystalline  or  amorphousform of drug.
3 FTIR, NMR, Raman spectra To find out the complex formation betweendrug and carrier.
4 Scanning Electron Microscopy To find out the particle size and shape.
5 Dissolution rate / diffusion rate 
studies
Rate and extent of dissolution.
   6 Thermodynamic study Degree of crystallinity
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Pharmacology of fungal infection.57
Fungal infections are termed as mycoses. Fungal infections are generally classified in to
two types 
1. Superficial fungal infections.
2. Systemic fungal infections.
1. Superficial fungal infections:
These superficial fungal infections are classified in to two types 
a. Dermato mycoses.
b. Candidiasis.
Dermatomycoses are infections of the skin, hair and nails. Most commonly caused by
Trichophyton, microsporum and epidermophyton spp. which caused by various types of
“ring worm” or tine a, tine a capitis affect the scalp. Tinea cruris, groin, Tinea pedis. In
superficial  candidiasis  the  yeast  like  organism  infects  the  mucous  membrane  of  the
mouth, vagina, and skin.
2. Systemic fungal infections 
Systemic  fungal  infections  are  caused  by  yeast  like  organism.  Other  more  serious
conditions are cryptococcal meningitis or endocarditis invasive pulmonary aspergillosis is
now a leading cause of death.
Drugs used in fungal infection 
1. Superficial acting drugs:
Terbinafine, Clotrimazole, Nystatin, Miconazole nitrate.
2. Systemically acting drugs:
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Fluconazole, Itraconazole, Amphotericine –B, Flucytosine
Griseofulvin, Potassium iodide, Terbinafine.
REVIEW OF ITRACONAZOLE
1.  Improved  solubility  of  Itraconazole  in  water  significantly  increased  as  the
concentrations  of  HP-β-CYD  increases,  showing  an  AP  type  phase  solubility
diagram. The upward curvature closely corresponded to the simulation curve which
was calculated on the basis of the 1:2 (guest: host) complexation model. The 1:2
complexes were formed even in the presence of 10% v/v propylene glycol, although
the  co-solvent  system made  the  interaction  with  HP-β-CYD weaker  due  to  the
competitive inclusion. The ultraviolet spectroscopic studies also supported the 1:2
complex formation of Itraconazole with HP-β-CYD in 10% v/v propylene glycol:
water  solution  at  pH 2.0  the  1H-NMR spectroscopic  studies  suggested  that  the
triazole and triazolone moieties of Itraconazole are involved in the 1:2 inclusion
complexation. K. Uekama., et al; (1999)58
2.  Solid dispersion of Itraconazole was prepared by various pH-independent and pH-
dependent  hydrophilic  polymers  are  characterized  by  differential  scanning
calorimetry,  powder  X-ray diffraction  and  scanning  electron  microscopy.  Of  the
polymers tested, pH-dependent hydrophilic polymers, AEA® and Eudragit® E 100,
resulted in highest increases in drug solubility (range, 141.4–146.9-fold increases).
The shape of the solid dispersion particles was spherical, with their internal diameter
ranging  from  1–10  mm.  The  dissolution  rate  of  Itraconazole  from  the  tablets
prepared by spray drying (SD-T) was fast, with \90%  released within 5 min. SD-T
prepared with AEA® or Eudragit® E 100 at a 1:1 drug to hydrophilic polymer ratio
(w:w)  showed  approximately  70-fold  increases  in  the  dissolution  rate  over  a
marketed product. © 1999 Published by Elsevier Science B.V. Sun Dong Yoo.,  et
al;(1999).59
`
3.  Solid  solutions  of  Itraconazole,  a  water  insoluble  antifungal,  for  improved
dissolution and improved bioavailability.  Influence of processing factors  on drug
and  carrier  properties  in  solid  solution  and  subsequently  on  drug  dissolution
13
behavior was also studied. An optimized solid solution formulation was compared
with marketed product in healthy human subjects under fasted and fed conditions
for  bioequivalence.  Polyethylene glycol (PEG) and drug were made into a  solid
solution at  120 °C. The cooled,  solid solution was then ground into granules  of
different sizes. Solid solutions of lower drug concentration dissolved at a faster rate,
and drug dissolution improved considerably with increasing molecular weight of
PEG. Initial  treatment of Itraconazole with the wetting agent/co-solvent  glycerol
prior to making Itraconazole into solid solution improved drug dissolution, and also
reduced the PEG amount required to dissolve drug to form solid solution. Addition
of a polymer such as HPMC to the solid solution eliminated precipitation of drug
following  dissolution.  As  the  granule  size  of  the  solid  solution  was  reduced,
precipitation  of  drug  during  dissolution  became  prominent.  Equivalence  of  two
formulations could not be shown for pharmacokinetic parameters Cmax and AUC,
under both fasting and fed conditions. Kapsi., et al; (2001) 60
4. Solid  dispersions  containing  different  ratios  of  Itraconazole  and  Hydroxypropyl
methylcellulose  (HPMC)  were  prepared  by  solvent  casting.  Based  on  dose,
differential  scanning calorimetric  and dissolution results,  a drug/polymer ratio of
40/60 w/w was selected in order to prepare dispersions by melt extrusion. The melt
extrusion process was characterized using a design of experiments (DOE) approach.
All parameter settings resulted in the formation of an amorphous solid dispersion
whereby  HPMC  2910  5  Map’s  prevents  re-crystallization  of  the  drug  during
cooling.  Dissolution  measurements  demonstrated  that  a  significantly  increased
dissolution rate was obtained with the amorphous solid dispersion compared to the
physical mixture. The outcome of DOE further indicated that melt extrusion is very
robust  with  regard  to  the  Itraconazole/HPMC  melt  extrudate  characteristics.
Stability studies demonstrated that the Itraconazole/HPMC 40/60 w/w milled melt
extrudate formulation is chemically and physically stable for periods in excess of 6
months as indicated by the absence of degradation products or re-crystallization of
the drug. Geert verreck., et al; (2003) 61
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5. Solid dispersion formulations of Itraconazole in human volunteers in comparison
with Sporanox®, the marketed  form.  Solid  dispersions  made up of  Itraconazole
(40%,  w/w)  and  HPMC  2910,  Eudragit  E100  or  a  mixture  of  Eudragit  E100-
PVPVA64 were manufactured by hot-stage extrusion and filled in gelatin capsules.
The formulations were tested in eight human volunteers in a double blind, single
dose, and cross-over study. Concentrations of the drug and its metabolite hydroxy
Itraconazole in the plasma were determined using HPLC. The in vivo performance
was evaluated by comparing the mean area under the plasma concentration–time
curves (AUC),  the mean maximum plasma concentration (Cmax),  and the  mean
time  to  reach  Cmax  (Tmax).  The  mean  bioavailability  of  Itraconazole  was
comparable  after  administration  of  the  HPMC  solid  dispersion,  compared  to
Sporanox®,  while  it  was  lower  after  administration  of  the  Eudragit  E100  or
Eudragit E100-PVPVA64 dispersions. Due to high variability, a significant decrease
in AUC and  Cmax was only observed for the Eudragit E100-PVPVA formulation.
Although the solid dispersions showed different in vitro dissolution behavior, Tmax
values were comparable. The same observations with respect to AUC,  Cmax and
Tmax could be made for hydroxy Itraconazole. The present results indicate that hot-
stage extrusion can be considered as a valuable alternative for manufacturing solid
dispersions of Itraconazole. Guy Van den Mootera, et al; (2005) 62
6. Reported an improve the solubility and dissolution rate of a poorly water-soluble
drug Itraconazole,  by Cooling curve method was used to  determine the eutectic
point of drug-Poloxamer 188 mixture and the phase diagram of the binary system
was constructed. Solid dispersions of Itraconazole were prepared by the hot melt
method and characterized by differential scanning calorimetry (DSC). Solubility and
dissolution  studies  in  various  media  were  conducted  with  pure  Itraconazole,  a
physical mixture and solid dispersions. Solubility studies indicated that poloxamer
188 increased significantly the solubility of Itraconazole in water (range 33.40- to
176.8-fold increases).  The  eutectic  mixture  resulted  in  highest  increases  in  drug
dissolution  rate.  The  cumulative  release  of  Itraconazole  from  solid  dispersions
within  60  min  was  4.66  times  higher  than  the  pure  drug  in  0.1  ml  HCl.  The
dissolution of Itraconazole from solid dispersions in Poloxamer 188 with a eutectic
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composition reached a satisfactory level (above 90%) after 20 min in both water
(0.5% SDS)  and  pH 6.58  PBS  buffer  (0.5% SDS). An increased  solubility  and
dissolution ate of Itraconazole can be achieved by forming a eutectic mixture using
Poloxamer 188 as a carrier. The drug dissolution rate was highest at a drug-polymer
ratio of 5: 95 (w/w). Siling Wang ., et al ; (2006).63
7. Self-emulsifying drug delivery system (SEDDS) composed of oil, surfactant and co-
surfactant  for  oral  administration  of  Itraconazole  was  formulated,  and  its
physicochemical  properties and pharmacokinetic parameters of Itraconazole were
evaluated. Among the surfactants and oils studied, Transcutol\, Pluronic\ L64 and
tocopherol acetate were chosen that showed the maximal solubility to Itraconazole.
The solubility of Itraconazole was further improved by the addition of hydrochloric
acid.  Droplet  size of  Itraconazole emulsion was kept  constant  both in simulated
gastric  fluid  without  pepsin  (pH  1.2)  and  simulated  intestinal  fluid  (pH  6.8)
throughout 120-min incubation period. Itraconazole in the SEDDS rapidly dissolved
in every dissolution medium whereas the Sporanox\ showed different  dissolution
patterns during the 120-min incubation according to the dissolution media. In fasted
and  fed  normal  diet  group,  AUC0Y24  h  and  the  mean  maximum plasma  level
(Cmax) of Itraconazole after oral administration of SEDDS in rats were comparable
to those of Itraconazole after oral  dose of Sporanox\.  However,  in fed lipid diet
group, AUC and Cmax after oral administration of SEDDS in rats were 3.7- and
2.8-fold  higher,  respectively,  compared  with  those  of  Sporanox\.  These  results
demonstrate  that  the  SEDDS of  Itraconazole composed of  Transcutol\,  Pluronic\
L64 and tocopherol acetate greatly enhanced the bioavailability of Itraconazole after
the dose, particularly not influenced by food intake or not. Thus, this system may
provide  a  useful  dosage  form for  oral  water-insoluble  drug without  food  effect.
Chong –kook Kim., et al ; 2006. 64
8. An  enhanced  dissolution  and  bioavailability  characteristics  of  Itraconazole.  By
Inclusion complexes between Itraconazole and β-cyclodextrin were prepared using
simple  physical  mixing,  conventional  co  precipitation  method,  and  supercritical
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carbon dioxide (SC CO2). Effects of process variables (temperature, pressure) and
drug:  cyclodextrin  ratio  on  inclusion  yield  and  thermal  behavior  of  the  solid
complexes prepared by SCCO2 were studied and compared to those obtained by
physical mixing and co precipitation methods. In addition, dissolution amounts of
the products obtained by different methods were measured in gastric fluid. Finally,
pharmacokinetic studies of the inclusion complexes were conducted in male Wister
rats to assess the bioavailability of the prepared complexes.  Results  showed that
temperature, pressure and Itraconazole: cyclodextrin ratio had significant effects on
the inclusion yield of the complex prepared by SC CO2 method. Higher inclusion
yields were obtained in the SC CO2 method as compared to physical mixing and co
precipitation  methods.  In  vivo  drug  pharmacokinetic  studies  showed  that  the
Itraconazole-β-cyclodextrin  product  prepared  using  SC  CO2  gave  higher
bioavailability of Itraconazole (in blood, liver and kidney of male Wister rats) as
compared to the products obtained by physical mixing or co precipitation methods.
Ali H. Al-Marzouqi., et al (2007) 65
9. Solid dispersion containing pellets  of Itraconazole for  enhanced drug dissolution
rate. The influence of process parameters used during high shear pelletization on the
pellet properties including pellet size and dissolution rate was also studied. Solid
dispersions  of  Itraconazole  were  prepared  with  Eudragit®  E100,  a  hydrophilic
polymer, by a simple fusion method followed by powdered and characterized by
differential  scanning calorimetry and X-ray powder diffraction.  Solid dispersions
containing pellets were consequently prepared using a lab-scale high shear mixer. In
order to improve the product quality,  a  central  composite  design was applied to
optimize the critical process variables, such as impeller speed and kneading time,
and  the  results  were  modeled  statistically.  Itraconazole  was  presented  as  an
amorphous state in the solid dispersion prepared at a drug to polymer ratio of 1:2.
Both  studied  parameters  had  great  effect  on  the  responses.  Powdered  solid
dispersion  and  pellets  prepared  using  the  optimal  parameter  settings  showed
approximately 30-  and  70-fold  increases  in  dissolution  rate  over  the  pure  drug,
respectively. Solid dispersion prepared by simple fusion method could be an option
for Itraconazole solubility enhancement. Pelletization process in high shear mixer
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can be optimized effectively by central composite design. Siling Wang., et al (2007)
66
10. Investigated the feasibility of a supercritical  fluid process,  called aerosol  solvent
extraction  system  (ASES),  for  producing  solid-state  inclusion  complexes  of
itraconazole  (ITR)  with  2-hydroxypropyl-β-cyclodextrin  (HP-β-CD).  ITR  was
complexed with HP-β-CD at temperatures of 35–55  ◦C, pressures of 83–140 bar,
CO2 densities of 0.498–0.801 g/cm3, and solution concentrations of 1–5% (w/v).
The  ASES-processed  inclusion  complex  powders  were  observed  to  consist  of
agglomerates of very fine (100–500 nm) particles. From the experimental results of
X-ray  diffraction  and  differential  scanning  calorimetry,  it  was  found  that  ITR
intermolecular interacted with the HP-β-CD cavity,  resulting in  the formation of
inclusion  complex.  Furthermore,  the  ASES-processed  ITR/HP-β-CD  powders
showed a significant enhancement in the ITR solubility (up to 753.6 µg/mL) in an
aqueous medium of pH 1.2. The aqueous solubility of ITR increased with pressure
at a constant temperature, and we could obtain a relatively high solubility of 341
µg/mL at 140 bar and 35 ◦C. In a solution concentration range of 1–5% (w/v), the
solubility increased with decreasing concentration, yielding 289–407 µg/mL. When
the molar ratio of ITR to HP-β-CD was varied from 1:1 to 1:3, the ITR solubility
increased with HP-β-CD content, giving a value of 753.6 µg/mL for the 1:3 ratio.
For the ASES-processed ITR/HP-β-CD powders, the percent dissolution of ITR also
increased  considerably  and  about  90% of  ITR  was  dissolved  within  5–10  min.
Jong-Hoon Ryua,. et al: (2008)
11. Domperidone is a widely used antiemetic, poorly water soluble drug, erratically
absorbed in stomach and possess several dissolution-related problems thus it  has
poor bioavailability. Solubility of a drug plays a very important role in dissolution
and hence absorption of drug which ultimately affects its bioavailability. Hence, by
considering  the  facts  related  to  drug,  attempts  have  been  made  to  formulate
inclusion complexes using methylated β-cyclodextrin and also to study the effect of
preparation  method.  Inclusion  complexes  were  prepared  using  methylated  β-
cyclodextrin in 1:1 and 1:2 molar ratios. Kneading, ultrasonification and physical
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mixture method were used for preparation of inclusion complexes. All the inclusion
complexes  were  characterized  using  FTIR,  DSC  and  XRD.  The  solubility  and
dissolution results revealed that there was a considerable increase in solubility and
dissolution of all inclusion complexes as compared to pure drug. It was highest in
case of methylated β-cyclodextrin in 1:1 molar ratio using ultrasonification method
(USM1). Stability study revealed that all complexes were stable for a period of three
months. Dhananjay S Ghodkea., et al: (2008) 68
12. Investigated  the  influence  of  temperature  and  moisture,  polymer  blends  of
polyethylene glycol 6000 (PEG 6000) and hydroxypropylmethylcellulose 2910 E5
(HPMC 2910 E5) and solid  dispersions  of itraconazole in  these polymer  blends
were spray dried, further dried for 2 weeks and stored at three different conditions:
25ºC, 0% relative humidity (RH); 25ºC, 52% RH; 60ºC, 0% RH. MTDSC analysis
of the polymer blends revealed that at 25ºC, 52% RH, PEG 6000 recrystallized to a
high extent. At 60ºC, 0% RH the two polymers were miscible, probably due to the
removal of bound water. In the ternary dispersions the polymers behaved similarly.
The crystallinity degree of itraconazole in samples stored at 25ºC, 52% RH and at
60ºC,  0% RH was  increased  compared  to  the  samples  stored  at  25ºC,  0% RH,
probably due to the plasticizing effect  of  moisture  at  25ºC,  52% RH and to  an
increased  mobility  at  60ºC,  0%  RH.  XPS  analysis  revealed  a  redistribution  of
itraconazole at the surface as Itraconazole recrystallized from the blend. Dissolution
tests revealed that a decrease in the itraconazole release was directly related to its
crystallinity degree, no correlation was found with the crystallinity degree of PEG
6000. Guy Van den Mooter., et.al: (2008)
13. Solid dispersions was prepared by co-spray-drying of TPGS-stabilized Itraconazole
Nanosuspension with Aerosil®200, followed by heat treatment of the powders. The
Itraconazole/Aerosil®200 weight ratios amounted to 50/50, 30/70, 40/60 and 20/80.
The Itraconazole  content  of  the  powders  was  close  to  the  expected  value,  with
relative errors between 0.3% and 7.8%. X-ray powder diffraction (XRPD), solid
state NMR (SSNMR) and differential scanning calorimetric (DSC) evaluation on
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the powders revealed the formation of amorphous Itraconazole and the absence of
glassy  Itraconazole.  Dissolution  of  the  powders  was  enhanced  compared  to
crystalline  and  glassy  Itraconazole  (a  2-dimensional  structured  form  of
Itraconazole). However, no clear trend could be observed between drug loading and
dissolution  performance  of  the  solid  dispersions.  Upon  storage,  conversion  to
crystalline  Itraconazole  was  observed  for  the  50/50  powder  based  on  XRPD,
SSNMR  and  DSC  measurements.  Although  the  40/60  powder  remained  X-ray
amorphous upon storage, DSC did reveal that a small fraction (7.5±1.6% after 10
months  of  storage)  of  Itraconazole  crystallized upon  storage.  For  the  30/70  and
20/80 dispersions, no crystallization could be seen. After 10 months of storage, an
important  change  in  the  dissolution  behavior  of  the  powders  was  observed.  A
decrease in dissolution performance was seen for the 50/50 dispersion, which could
be attributed to the crystallization of Itraconazole.  On the other hand, the 40/60,
30/70 and 20/80 dispersions showed an increase in dissolution rate (more than 60%
after 10 min). Although not completely clear at this stage, adsorption of Itraconazole
onto the Aerosil®200 surface during storage might be responsible for this behavior.
Finally, in vivo experiments were performed in the rat. Oral bioavailability of the
30/70  dispersion  was,  although  lower  compared  to  the  marketed  Sporanox®
formulation, significantly enhanced compared to the crystalline drug. Guy van den
mooter., et al; 2009.69
14. Improved dissolution and in vivo bioavailability of  Itraconazole prepared by the
solid  dispersion  using lipid  materials  as  inert  excipients.  The  drug  encapsulated
dispersions are spray dried and are duly characterized for drug content, particle size
distribution, drug morphological conversion, drug compatibility with the excipients,
in vitro  dissolution and  in  vivo  bioavailability.  The drug content  in the prepared
dispersions is between 80.0% and 95.0% (w/w) of the theoretical  values and the
mean volume diameter (VMD) of the particles collected from drying chamber and
cyclone are found to be 21.65 & 33.66µm, respectively. The DSC thermo grams
have indicated the morphological conversion of Itraconazole to amorphous form.
The saturation solubility for Itraconazole in the spray dried formulation is 5.2 and
2.6 times higher to the plain drug and spray dried drug, respectively. The dissolution
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of Itraconazole in acetate buffer pH 1.2 is 69% in the solid dispersion formulation
where  as  it  is  only 17% in the plain  drug in  60  min.  And the enhancement  of
dissolution is 4.07 times higher to plain drug after 60mins. The formulations have
demonstrated the significant improvement of bioavailability (AUC=14384ng/h/ml)
compared  to  plain  drug  suspension  (AUC=4384ng/h/ml).  These  results
demonstrated the efficacy of  solid  lipid  dispersions  for the enhancement  of  oral
bioavailability of Itraconazole by increasing its aqueous solubility. R.S Prasad., et
al; (2010) 70
BACKGROUND OF THE STUDY
Itraconazole is a poorly soluble antifungal agent and so its bioavailability remains
problematic  solid  dispersion  approach  using  different  inert  carriers  and  inclusion
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complex with β- cyclodextrins have been investigated and an improved dissolution and
bioavailability of Itraconazole reported. Itraconazole is a weak base and so absorption of
drug  is  influenced  by physiological  pH of  the  environment  to  which  it  is  exposed.
Itraconazole  absorption is  improved  by the presence  of  food in  the  stomach due  to
increase in pH, previous study showed an improved dissolution and pharmacokinetics of
Itraconazole β- cyclodextrin  inclusion complex in gastric fluids in animal model and the
results compared between inclusion complex prepared by physical mixture, conventional
co-precipitation  method  and  super  critical  carbon  dioxide  (SC  CO2).  However  the
influence of different pH conditions of the stomach on the dissolution and bioavailability
of  Itraconazole  -  β-cyclodextrin  inclusion  complex  prepared  by  conventional  co-
precipitation method is lacking and hence the present study to investigate the same.
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CHAPTER - III
    PROFILES
3.1 DRUG PROFILE
Itraconazole is an orally active triazole anti-fungal agent.71 Itraconazole, which
was first synthesized in 1980,  Itraconazole having broad spectrum of activity against a
number  of  fungal  species  like  histoplasmosis,  blastomycosis  and  onychomycosis.72
including  Dermatophytes,  Such  as  Malassesia  fur-fur,  Candida  species,  Aspergillus
species, and Histoplasma capsulatum var. capsulatum.
Itraconazole is an extremely weak base (PKa = 3.7) which is virtually unionized at
physiological PH.73,74  it is also very lipophilic with Octanol /water log partition coefficient
of  5.66 at a  PH of  8.1. The drug has a  PH dependent Dissolution resulting in low and
variable  oral  absorption.  The  absorption  of  the  drug  is  enhanced  by  the  concurrent
administration  of  food.75  Based  on  the  Biopharmaceuticals  classification  system,
itraconazole is an example of class II compounds.39Meaning that its oral bioavailability of
the drug is dissolution rate limited.
Chemical Structure: 76
                                     
CHEMICAL NAME: 76
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Itraconazole 
 (cis-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-
yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-5-methyl-2-(3-methylbutyl)-3H-
1,2,4-triazol-3-one)
                                         Molecular formula      :    C35H38Cl2N8O4
                                         Molecular weight        :    705.64
                                         Melting point               :    166°c    to   170°c
                                         Half life                        :     21hours
                                         Protein binding           :      99%
                                         Bioavailability            :     55%
               Synonym                  :    Sporanox, Itrizole, Fungitra,
                                                                    Triasporm, Sopranos, Oriconazole
Physicochemical properties:
           Itraconazole is almost white to half white powder. Partially in-soluble in water,
and freely soluble in methylene di-chloride, sparingly soluble in Tetrahydrofuran, very
slightly soluble in the alcohol.
 Mechanism of action: 76
The triazoles have a similar mechanism of action to that of the imidazoles. The
free azole nitrogen competes for oxygen at the catalytic heme iron atom of cytochrome P-
450  enzymes.  Inhibition  of  cytochrome  P-450  enzymes  prevents  the  synthesis  of
ergosterol  in fungal cell membranes by limiting the C-l4 demethylation of lanosterol,
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which is critical for the synthesis of ergosterol. Lack of ergosterol alters the membrane
fluidity and steric relationships of other membrane-associated enzymes and also results in
an  accumulation  of  phospholipids  and  unsaturated  fatty  acids  within  fungal  cells.
Itraconazole  binds  only weakly to  mammalian  cytochrome P-450  and  it  has  a  much
higher affinity than ketoconazole for fungal P-450 enzymes.
 Pharmacokinetics:
Fig. 1:  Pharmacokinetic absorption of Itraconazole
The drug is absorbed in to the systemic circulation and it is highly bound to the
plasma  proteins.  Plasma  concentration  of  the  drug  is  low.  The  drug  is  extensively
metabolized by the liver by cytochrome P450 3A4 iso-enzyme (CYP3A4) which results
in production of both active and inactive metabolites. Hydroxy metabolites are active77
Dissolution rate of itraconazole is optimal at a pH 1-4, impaired absorption occurring
above these pH values. Gastric emptying rate also plays an important role in absorption
of  itraconazole.78 Absorption  of  drug  is  influenced  by  the  food.  Food  increases  the
absorption the drug. The active and in active metabolites are clear by the kidney half of
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the drug under go by the first pass metabolism.79 Unchanged drug is excreted by the feces
(3-18%). 
 Metabolism76
The  main  metabolic  Path  ways  are  oxidative  scission  of  the  dioxolane  ring,
oxidative degradation of the piperazine ring and aliphatic oxidation and ‘N-dealkylation
at the l-methylpropyl substituent. 
Therapeutic uses: 
It is used in the treatment for several fungal infections, commonly used to treat
Toenalis.  Effective  in  treating  pulmonary  infections  like  blastomycosis  and
histoplasmosis. It is active against. Dermatophytes, Malassesia fur - fur, Candida species,
Aspergillus  species,  and  Histoplasma  capsulatum  var.  capsulatum.  it  is  used  in  the
treatment of the veginal candidacies. It  is also a first line treatment in many types of
fungal infections like skin, nails, mucocutaneous and oropharyngel infections.
 Dosage:
In treating deep mycoses, a loading dose of 200mg of itraconazole is administered
three times daily for the first three days. For maintenance therapy two 100mg capsules
are twice daily with food. 
HIV: Maintenance  HIV infected patients  disseminated histoplasmosis  200mg daily is
used.
Onchy-mycosis can be treated with 200mg once daily for 12 weeks or 200mg twice daily
for one week out of each month so called pulse therapy. 
                                 Vulvovaginai 200 mg twice daily 1 day
                                  Candidiasis or 200 mg daily 3 days
                                  Pityriasis versicolor 200 mg daily 7 days
                                  Dermatophytosis 100 mg daily 15 days
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                                  Oral candidiasis   100 mg daily
                                   Fungal keratitis 200 mg daily
Highly keratinized regions as in plantar tine a pedis and palmar tine a manus require an
additional treatment of 15 days at 100 mg daily “Dose to be double in case of immune
suppression.15 days 21 days.
Drug interactions: 76
Enzyme-inducing drugs such as rifampicin and phenytoin significantly reduce the
oral  bioavailability  of  itraconazole.  Consequently,  monitoring  of  itraconazole  plasma
concentrations  is  advised  when  enzyme-inducing  agents  are  co-administered43.
Itraconazole can inhibit  the metabolism of  drugs  metabolized  by the  cytochrome 3A
family resulting in  an increase and or  a  prolongation of  their  effects,  including side-
effects. 
Examples are:
Terfenadine, Astemizole, Cisapride, Oral midazolam and triazolam. These agents
should not be used in patients treated with itraconazole. If midazolam is administered
intravenously,  special  precautions  are  required  since  the  sedative  effect  may  be
prolonged.80-86 
Warfarin, Digoxin, Cyclosporine-A and possibly tacrolimus. The dosage of these drugs, if
co-administered with itraconazole, should be reduced if necessary. 87
3.2 β -CYCLODEXTRIN
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Cyclodextrins  are  cyclic  oligosaccharides  containing  at  least  6  D-(+)
glucopyranose  units  attached  by  α-(1,  4)  Glucosidic  bonds.  (CDs),  They  were  first
discovered in 1891.25  The outside surface of these molecules is hydrophilic and the inside
surface hydrophobic,  They are able to include,  fully or  partially,  in their cavity large
organic molecules by non-covalent interaction.88-89 (hydrogen bonds, Vander-Wall forces).
Among  the  various  approaches  that  have  been  used  to  improve  the
solubility and dissolution rate of drugs, complexation with cyclodextrins is one of the
most promising ones. Which enhance their solubility, dissolution rate, chemical stability
and bioavailability and reduce their side effects and toxicity. 90
Conventional  methods for  the preparation of  solid  inclusion complexes
between  cyclodextrins  and  various  drugs  includes   kneading,  co-evaporation,  sealed-
heating,  co-grinding, spray-drying and freeze-drying.91  The use of supercritical  carbon
dioxide  (sc  co2)  has  been  recently  proposed  for  the  preparation  of  various  drug-
cyclodextrin inclusion complexes for enhanced solubility and dissolution rate.92,93
Cyclodextrins are of three types:  α, β, and, γ. Cyclodextrins, referred to as first
generation or parent cyclodextrins.  α, β, and, cyclodextrins are composed of six, seven
and  eight  α-(1,4)-linked  glycosyl  units,  respectively94  β-Cyclodextrin  is  the  most
accessible,  the  lowest-priced  and  generally  the  most  useful.  Cyclodextrins  is  able  to
improve  drug  delivery  through  biological  membranes.  The  cyclodextrin  are  high
molecular  weight  compounds  ranging  from  (1000  to  1500).There  are  numerous
applications for cyclodextrins in the pharmaceuticals field. For example, the addition of α
or  β  -cyclodextrin  increases  the  water  solubility  of  several  poorly  water-soluble
substances, and improve oral bioavailability, β- CD has been widely used in the early
stages of pharmaceutical applications because of its readily availability and cavity size
suitable for the widest range of drugs. But the low aqueous solubility and nephro toxicity
limited the use of β-CD especially in parenteraldrug delivery. Method of preparation by
co-grinding,  kneading,  solvent  evaporation,  co-precipitation,  spray  drying,  or  freeze
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drying can affect drug/CD complexation. The effectiveness of a method depends on the
nature of the drug and CD.95, 96, 97  In many cases, spray drying, 98-99 and freeze drying.100
were found to be most effective for drug complexation.
    Synonym                      :       Beta – cyclodextrin, βCD, BCD, β-Sachardinger 
                                                   Dextrin cyclodextrin B, cycloamyloses,             
                                                    Cyclomaltoses and Schardinger dextrins 
               Chemical formula       :         (C6H10O5)7
    Molecular weight        :         1135.00
Solubility                      :         Sparingly soluble in water, Freely soluble in hot
                                                   Water Slightly soluble in alcohol
                 Structure :95
            
                         
                       
The chemical structure (A) and the toroidal shape (B) of the cyclodextrin molecule
Table.3:  Some characteristics of (α, β, γ, δ).
Type of CD Cavity diameter A Molecular weight Solubility(g/100ml)
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α – CD 4.7 – 5.3 972 14.5
β  - CD 6.0 – 6.52 1135 1.85
γ  - CD 7.5 – 8.3 1297 23.2
δ  - CD 10.3 -11.2 1459 8.19
Mechanism of formation of Inclusion complexes:
Cyclodextrins are able to form solid inclusion complexes (host–guest complexes)
with a wide range of solid, liquid and gaseous compounds by a molecular complexation.
103  in these complexes, a guest molecule is held within the cavity of the cyclodextrin host
molecule. Complex formation is a dimensional between host cavity and guest molecule
104  The lipophilic  cavity  of  cyclodextrin  molecules  provides  a  microenvironment  into
which appropriately sized non-polar moieties can enter to form inclusion complexes.105
No covalent bonds are broken or formed during formation of the inclusion complex.106
Complexes  can  be  formed  either  in  solution  or  in  the  crystalline  state  and  water  is
typically the solvent  of choice.  Inclusion complexation can be accomplished in a co-
solvent system and in the presence of any non-aqueous solvent.
                                             
Drug + CD = Drug: CD Complex
               
                                  Fig 2:  Itraconazole and beta cyclodextrin inclusion complex.
 Applications of cyclodextrins
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           Since  each  guest  molecule  is  individually  surrounded  by a  cyclodextrin
(derivative) the molecule is  micro-encapsulated from a microscopically point of view.
This can lead to advantageous changes in the chemical and physical properties of the
guest molecules.
i. Stabilization of light or oxygen-sensitive substances.
ii. Modification of the chemical reactivity of guest molecules.
iii. Fixation of very volatile substances.
iv. Improvement of solubility of substances.
v. Modification of liquid substances to powders.
vi. Protection  against  degradation  of  substances  by
microorganisms.
vii. Masking of ill smell and taste.
viii. Masking pigments or the color of substances.
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  PLAN OF WORK
Qualitative analysis of drug
    Preparations
Evaluation of physical mixture’s 
and co-precipitates. [Itraconazole 
and β- cyclo dextrin in 1:2 and 1:4]
 mixture [Itraconazole and β- 
cyclo dextrin in 1:2 and 1:4]
Calibration curve of 
Itraconazole in PH (1.2, 
2.0, 3.0, 4.0)
Co-precipitate [Itraconazole and β- 
cyclo dextrin in 1:2 and 1:4]
In-vitro dissolution study
Physical characterisation of pure drug, 
physical mixtures and co-precipitate In-vivo pharmacokinetic study 
of best formulation in rabbits.
FTIR analysisPhase     solubility
study
DSC analysis
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5.  AIM AND OBJECTIVE
AIM:  To  investigate  dissolution  and  in–vivo bioavailability  of  itraconazole  β  –
cyclodextrin complex.
OBJECTIVE: The following studies were performed.
 Phase solubility study.
 FTIR spectra.
 Differential scanning calorimetric. 
 In-vitro dissolution.
 In-vivo pharmacokinetic study.
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         MATERIALS 
6. Materials
S.no Drugs and chemicals Manufacturer/ supplier
1. Itraconazole usp Hetero Pvt. Ltd
2. β- cyclodextrin Hi-media laboratories Pvt.Ltd
3. Methanol Loba Chemie Pvt.Ltd.
4. Tragacanth Loba Chemie Pvt.Ltd.
5. Alcohol Loba Chemie Pvt.Ltd.
Table.4
S.no Drugs and chemicals Manufacturer/ supplier
1. UV-Spectrophotometer Perkin Elmer
2.
Infra-Red
Spectrophotometer Perkin Elmer spectrum RX1 FT-
IR
3. Differential Scanning
Calorimetry
Schimadzu, DSC 60.
4. Weighing Balance Schimadzu
Table .5
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7. METHODOLOGY
7.1 Procedure for calibration curve of Itraonazole 
 Preparation of Calibration Curve.
Itraconazole content was estimated by measuring the absorbance at 265nm. The standard
curve for Itraconazole was prepared by using different pH [1.2, 2.0, 3.0, 4.0,]
Procedure  
       100mg of the Itraconazole was dissolved in different pH [1.2, 2.0, 3.0, 4.0,] and
shaken well and sonicated for 5min to get a clear solution and make up the volume to
100ml with the buffer. From the stock solution take 10 ml and make up the volume to
100ml. From the working standard take 2, 4, 6, 8, 10 ml and diluted to 10 ml to get the
concentrations of 2, 4, 6, 8, 10(µg/ml) Graphs was Plotted by taking time on X- axis and
concentration on Y- axis.  
7.2 Preparation of physical mixture
 The physical mixtures was prepared by gently grinding the drug and cyclodextrin
powders in a mortar in the ratio of 1:2 and 1:4 and they were pulverized and then mixed
thoroughly in glass mortar and pestle until homogenous mixture is Obtained. Mixtures
were passed through 0.45 µm sieve and used for further studies.
7.3 Preparation of the inclusion complexes by co- precipitation method
Required  amount  of  β-cyclodextrin  was  dissolved  in  de-ionized  water  and  a
known amount of Itraconazole (100mg) (giving the desired drug to b-cyclodextrin molar
ratio) was dissolved in methanol. The two solutions are heated to 65ºC and added to
gather after completely dissolved. The final solution was then mixed continuously with a
magnetic stirrer while heating at 65ºC and allowed, the organic solvent was allowed to
evaporate and the mixture was cooled to 5ºC. The crystals were separated by filtration
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through  0.45µm  membrane  filters.  The  sample  was  then  dried  and  stored  at  room
temperature.
7.4   In- vitro dissolution study
Dissolution profile  of  pure Itraconazole,  physical  mixture and solid  dispersion
were evaluated according to the method described in USFAD 900mL of the dissolution
medium of different  buffer pH (1.2,  2, 3,  4) was prepared with de-aerated water and
placed in the vessel and temperature of medium was maintained at 37±0.5oC. The sample
was placed in the medium and the dissolution was performed at 100 rpm. 10 ml samples
were  withdrawn  at  5,  10,  20,  30,  45,  60.min  and  equivalent  amount  of  dissolution
medium were added to maintain the sink condition. The obtained samples were filtered
(0.45 µm pore size) and analyzed by Spectrophotometer at 265nm the experiments were
carried out in triplicate and mean values and SD were recorded.
7.5.   In – vivo bioavailability studies 
Animals:   
  New Zealand white rabbits of either sex weighing 1.5 to 2.5kg were housed in
animal house of Swamy Vivekanandha College of Pharmacy. The animals were fed with
cabbage, and water. They were maintained in standard laboratory conditions 21±2 0C and
relative humidity of 55-60%. The animals were overnight fasted before the experiment.
The study protocol was approved by the Institutional Animal Ethical Committee and the
protocol number is SVCP/IAEC/M.Pharm/03/2011.
            Sex                            :        Both Male and Female
           Number of animals    :        9                           
           Animal Dose              :      17.85mg Itraconazole sample.
                                         Itraconazole physical mixture in 1:4 (33.55mg)
                                         Itraconazole co- precipitation in 1:4 (30.7mg)
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7.6.   Procedure for collection of blood from marginal ear vein:
The animal was placed in restrainer.  Smoothly shaved the hair of the ear with
blade without disturbing the blood vessels. Ear was cleaned with 95% v/v alcohol on the
collection site and rapid rubbing on the ear to  dilate blood vessels which is  easy to
collect the blood. 24G needle was used to collect the blood from marginal ear vein. After
collecting blood, clean sterile cotton was kept on the collection site and finger pressure
was applied to stop the bleeding.
 Experimental  procedure: Rabbits  were  classified  into  3  different  groups  each  group
consisting of 3 animals. 
Each group of rabbits received the sample through an intra gastric tube. 1ml of
blood was collected from each rabbit through marginal ear vein and placed in heparinized
tubes at a time interval of 0, 0.5, 1, 1.5, 2, 4, and 8 hrs  after sample administration and
plasma was separated by using centrifugation at 4000 rpm and stored at -4⁰C, samples
were analyzed by validated high performance liquid chromatography (HPLC). 
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7.7. Extraction of Itraconazole from plasma samples. 
Blood sample was collected in tubes coated with EDTA. After sampling tubes are
Centrifuged for 30 min at 4000 rpm at room temperature and the plasma was removed
and stored at  −  4⁰C until  tested.  Stability of  the analytes  under these conditions was
verified. Three hundred micro litres of acetonitrile was added to the plasma and the tubes
were thoroughly mixed on a vortex mixer. The tubes were centrifuged for 5 min, and the
supernatant was analyzed by RP-HPLC. Itraconazole standards (DSM Pharma Chemicals
Inc.,  South  Haven,  and  MI)  were  prepared  in  plasma  and  treated  identically  to  the
samples.  The  assays  were  carried  out  using  with  an  Alltech  Altima  C18  column,
250mm×4.6 mm, 5µm column. A mobile phase of 36% 5mM sodium phosphate (pH 6.7),
58% acetonitrile and 6% methanol was run isocratically at 37  ⁰C at a flow rate of 1.1
ml/min.  Analytes  were  detected  by UV at  263 nm,  with  a  bandwidth of  10 nm and
fluorescence with 263 nm excitation and 380 nm emission. An injection volume of 100l
was used.
7.8. Pharmacokinetic parameters
The pharmacokinetic parameters were calculated for each rabbit  of  Group -  I,
Group-II, Group - III by the semi logarithmic plot of plasma itraconazole concentration at
various intervals. The following pharmacokinetic parameters were calculated:
 Kinetic  analysis  of  in-vitro  release  rates  of  itraconazole  and  β  –  cyclodextrin
complex.
The results of in-vitro release profile were plotted in modes of data treatment as
follows:
1.  Zero – order kinetic model - cumulative % drug released versus time.
2. First  – order kinetic model – log cumulative % drug remaining versus time.
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a)  Zero order kinetics:
Zero order release would be predicted by following equation.
                                                 At =A0 –K0t
Where,                                   At -   Drug release at time‘t’
                                                A0 -   Initial drug concentration
     K0 -   Zero-order constant (hr-1)
When the data is plotted as cumulative percent drug release versus time, if the plot 
is linear The data obeys zero order kinetics, with a slope equal to K0.
b)  First order kinetics:
First order release would be predicted by the following equation:
 
                                                   Log Co - Kt
                                                                    =    2.303
                      
                                                    Log C           
Where,
C = Amount of drug remained at time‘t’
Co = Initial amount of drug 
K = First order rate constant (hr-1)
When the data plotted as Log cumulative percent drug remaining versus time yields
a straight line, indicating that the release follow first order kinetics. The constant ‘K’ can
be obtained by multiplying 2.303 with slope values.
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1. Elimination rate constant(Ke): The elimination rate constant was determined using
the formula
Ke = -2.303 x slope of extrapolated curve
2. Elimination half life(t1/2) : t1/2 was calculated using the formula
T 1/2= 0.693/Ke
3. Absorption rate constant (Ka): This was determined by the method of residuals.
The log linear portion of the decline phase was back extrapolated for each curve.
The plasma concentration along this extrapolated line was C. the observed plasma
concentration C was subtracted from the corresponding extrapolated value at each
time point.  The semi logarithmic plot  of residuals (C-C) against time yields a
straight line.
Ka= -2.303 x slope of residual line
4. Absorption half life: It was calculated using the formula
T1/2(a) = 0.693/Ka
5. Apparent volume of distribution(Vd):It was calculated using the formula
Vd   =            Ka F X0
(Ka - Ke) y intercept
6. Time to Cmax(Tmax):Tmax was calculated using the formula
Tmax=        lnKa - lnKe
        Ka-Ke
7. Maximum plasma concentration (Cmax): Cmax was calculated using the formula
Cmax =    Y intercept (e-Ke. Tmax – e-Ka.Tmax)
8. Area under curve (AUC0-12): AUC0-12 was calculated using the formula
AUC   =       F X0
         Vd.Ke
9. AUC0-∞ was calculated using the formula
40
AUC0-∞ =     C0
          Ke
7.9. STATISTICAL ANALYSIS:
The values are expressed in mean ± SEM. One way ANOVA followed by Tukey-Kramer
multiple comparison tests.
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8.  RESULTS
8.1 Compatability studies on Itraconazole and β- cyclo dextrin
The  FTIR  spectra  of  pure  drugs,  physical  mixture  and  Co-precipitation  of
Itraconazole  and  β  –cyclo  dextrin  are  shown  in  the  spectra  exhibited  presence  of
characteristic peaks of drugs in physical mixture indicating that there was no chemical
interaction between the Itraconazole and β –cyclo dextrin.
Table: 6 Comparative FTIR spectra of different formulations
Formulations
S.n
o
Groups Pur
e
ITC
Pur
e β-
CD
Phy.mi
x 1:2
Phy.mi
x  1:4
Co-
ppt1:
2
Co-
ppt1:
4
Range Property
1. C-H + + + + _ _ 2941.8
0
Bending
aromatic
2. N 3⁰-
Nitrogen
+ _ + + + + 3561.0 3⁰Nitroge
n
3. C-N 2⁰
Stretchin
g
+ _ + + + + 1554.8
5
2⁰Stretchi
ng
4. C-CH3 + _ + + _ _ 1390.8
5
Alkane
dimethyl
5. α, β- 5
Member
rings
+ _ + + _ _ 1699.4
9
5 Member
rings
6. C-H
bending
+ + + + + + 2893.70 Bending
7 OH 3⁰
Stretchin
g
_
+ + + _ _ 1304.04 Stretching
8 C-O
Stretchin
g
_
+ _ _ _ _ 1332.97 Stretching
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8.1 COMPATABILITY STUDIES ON ITRACONAZOLE AND β-
CYCLO DEXTRIN
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8.2   DSC PEAKS OF ITRACONAZOLE AND β – CYCLO DEXTRIN
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8.3 PHASE SOLUBILITY STUDY OF ITRACONAZOLE IN pH
(1.2, 2.0, 3.0, 4.0)
Phase Solubility Study
                                  Phase solubility study was carried out in order to ascertain the effect
of β- cyclodextrin on the solubility characteristics of ITC. The results are shown in Table
50  and  figure  88-91  Solubility  of  ITC  was  increased  as  the  concentration  of  β-
cyclodextrin increases in pH 1.2 and in remaining pH it is decreased compare to the pH
1.2.
Table 7: Comparative phase solubility study of Itraconazole(mcg/ml) in different pH
   buffers
S.n
o
β–
cyclodextri
n
(µg/ml)
pH 1.2 pH 2.0 pH 3.0 pH 4.0
1 0 1.5±0.3 1.3±0.1
6
1.2±0.18 1.102±0.13
2
2 10 2.7±0.1
2
2.0±0.7 2.4±0.34 2.6±0.164
3 20 3.3±0.6 3.5±0.2
6
3.2±0.11 3.4±0.173
4 30 5.2±0.5
1
4.7±0.5
1
4.4±0.21 4.8±0.185
5 40 8.1±0.2
3
7.9±0.9 7.6±0.16
8
7.2±0.561
0 5 10 15 20 25 30 35 40 45
0
1
2
3
4
5
6
7
8
f(x) = 0.14x + 0.94
R² = 0.97
Phase solubility of Itraconazole  in pH 1.2 buffer
Concentration of β- cyclo dextrin (mg/ml)
Fig :15
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f(x) = 0.16x + 1.02
R² = 0.93
phase solubility of Itraconazole  in pH 2.0 buffer
Concentration of β- cyclo dextrin (mg)
Fig :16
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phase solubility of Itraconazole  in pH 3.0 buffer
Concentration of β- cyclo dextrin (mg)
Fig : 17
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Phase solubility of Itraconazole in pH 4.0 buffer
Concentration of β- cyclo dextrin (mg)
Fig :18
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8.4: CALIBRATION CURVES OF ITRACONAZOLE IN DIFFERENT pH (1.2,
2.0, 3.0, 4.0)
Table 8: Calibration curve of Itraconazole in pH 1.2
Concentration
(µg/ml)
Absorbance
0 0
2 0.145
4 0.264
6 0.407
8 0.541
10 0.679
0 2 4 6 8 10 12
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
f(x) = 0.07x + 0
R² = 1
Calibration curve of Itraconazole in pH 1.2
Concentration (µg/ml)
Fig.19
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Table 9: Calibration curve of Itraconazole in pH 2.0
Concentration
(µg/ml)
Absorbance
0 0
2 0.269
4 0.351
6 0.447
8 0.554
10 0.623
-
0 2 4 6 8 10 12
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
f(x) = 0.07x + 0.01
R² = 0.98
Calibration curve of Itraconazole in pH 2.0
concentration  (µg/ml)
Fig. 20
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Table 10: Calibration curve of Itraconazole in pH 3.0
Concentration
(µg/ml)
Absorbance
0 0
2 0.135
4 0.298
6 0.424
8 0.571
10 0.684
0 2 4 6 8 10 12
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
f(x) = 0.07x + 0.01
R² = 1
Calibration curve of Itraconazole in pH 3.0 buffer
Concentration  (µg/ ml)
Fig .21
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Table 11: Calibration curve of Itraconazole in pH 4.0
Concentration
(µg/ml)
Absorbance
0 0
2 0.129
4 0.253
6 0.425
8 0.569
10 0.634
                           
0 2 4 6 8 10 12
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
f(x) = 0.07x + 0
R² = 0.99
Calibration curve of Itraconazole in pH4.0
Concentration  (µg/ml)
Fig .22 
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Table 12:  In-vitro drug release pure Itraconazole in pH 1.2
Time (min) Trial 1 Trial 2 Trial 3 Cumulative %
drug release*
5 13.4 12.8 12.6 12.93±0.41
10 14.8 16.3 15.7 15.63±0.75
20 22.8 21.9 23.5 22.733±0.8
30 25.6 27.0 25.5 26.03±0.83
45 31.5 32.4 30.8 31.563±0.8
60 34.5 36.1 34.6 35.063±0.89
0 10 20 30 40 50 60 70
0
5
10
15
20
25
30
35
40
In-vitro drug release of Itraconazole in pH 1.2 
Time (min)
Fig .23  
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f(x) = 0.51x + 8.22
R² = 0.87
Zero order release of Itraconazole in pH 1.2
TIme (min)
 Fig. 24  
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1.75
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1.95
2
2.05
f(x) =  - 0x + 1.96
R² = 0.91
First order release of Itraconazole in pH 1.2
Time (min)
 Fig . 25
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Table 13: In-vitro drug release of physical mixture 1:2 in pH 1.2
Time
(min)
Trial 1 Trial 2 Trial 3 Cumulative %
drug release
5 27.4 25.4 26.1 26.4±0.81
10 30.2 38.5 29.7 29.48±0.87
20 31.8 30.7 32.4 31.6±0.86
30 37.4 35.6 36.0 36.33±0.94
45 47.2 48.1 46.8 47.36±0.66
62
60 57.2 56.8 58.0 57.3±0.61
0 10 20 30 40 50 60 70
0
10
20
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40
50
60
70
In-vitro drug release of physical mixture1:2 in pH 1.2
Time (min)
Fig . 26
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f(x) = 0.74x + 14.6
R² = 0.82
Zero order release of physical mixture 1:2 in pH 1.2
Time (min)
Fig . 27
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f(x) =  - 0.01x + 1.94
R² = 0.9
First order release of physical mixture 1:2 in pH 1.2
Time (min)
Fig . 28
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Table 14:  In-vitro drug release of co-precipitation 1:2 in pH 1.2
Time
(min)
Trial 1 Trial 2 Trial 3 Cumulative %
drug release
5 24.5 30.65 34.2 32.2±1.8
10 37.2 40.7 38.5 38.8±1.7
20 45.0 47.8 42.9 45.2±2.4
30 56.4 52.9 57.3 56.1±1.2
45 68.9 65.7 63.5 67.3±1.6
60 73.5 70.4 75.8 73.2±2.7
0 10 20 30 40 50 60 70
0
10
20
30
40
50
60
70
80
In-vitro drug release of co- precopitation1:2 in pH 1.2
Time(min)
Fig . 29 
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Time(min)
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Table 15:  In-vitro drug release of physical mixture 1:4 in pH 1.2
Time
(min)
Trial 1 Trial 2 Trial 3 Cumulative %
drug release
5 24.4 26.4 23.7 24.8±1.4
10 33.2 32.7 35.08 33.6±1.2
20 39.6 43.4 41.7 41.5±1.9
30 55.3 53.6 56.3 55.0±1.3
45 59.3 57.3 60.4 59.0±1.5
60 66.8 68.2 65.8 66.9±1.2
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In-vitro drug release of physical mixture 1:4 in pH 1.2
Time (min)
Fig . 32 
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 Fig . 33 
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Table 16:  In-vitro drug release of co-precipitate 1:4 in pH 1.2
66
Time
(min)
Trial 1 Trial 2 Trial 3 Cumulative %
drug release
5 29.8 28.7 31.8 30.1±1.57
10 36.9 35.7 39.6 37.4±1.99
20 49.9 50.4 52.5 50.93±1.38
30 63.6 62.4 65.7 63.9±1.6
45 67.8 68.1 71.4 69.1±1.99
60 82.5 81.1 84.7 82.7±1.8
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In-vitro drug release of co-precipitate1:4 in pH 1.2
Time (min)
Fig . 35 
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R² = 0.86
Zero order release of co-precipitate1:4 in pH 1.2
Time (min)
 Fig. 36 
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Table 17:  In-vitro drug release of Itraconazole in pH 2.0
Time
(min)
Trial 1 Trial 2 Trial 3 Cumulative %
drug release
5 12.6 13.8 15.3 13.9±1.3
10 23.5 21.4 20.6 21.8±1.4
20 28.8 26.2 27.7 27.5±1.3
30 35.7 36.8 34.5 35.6±1.1
45 39.4 37.4 40.6 39.1±1.6
68
60 43.7 41.3 42.1 42.3±1.2
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Fig . 38  
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Table 18:  In-vitro drug release of physical mixture1:2 in pH 2.0
Time
(min)
Trial 1 Trial 2 Trial 3 Cumulative %
drug release
5 23.6 21.4 24.7 23.2±1.6
10 28.8 27.9 30.1 28.9±1.1
20 36.9 34.8 38.5 36.7±1.8
30 46.5 43.7 45.4 45.2±1.4
45 58.4 54.5 56.3 56.4±1.9
60 62.9 57.6 58.5 59.6±2.8
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In-vitro drug release of  physical mixture 1:2 in pH 2.0
Time (min)
Fig . 41
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f(x) = 0.87x + 14.62
R² = 0.86
Zero order release of physical mixture 1:2 in pH 2.0
Time (min)
Fig . 42 
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Table 19: In-vitro drug release of co-precipitation 1:2 in pH 2.0
Time
(min)
Trial 1 Trial 2 Trial 3 Cumulative %
drug release
5 22.5 24.6 25.4 24.16±1.49
10 34.9 36.7 38.2 36.6±1.6
20 45.4 44.3 46.9 45.53±1.30
30 62.7 59.3 60.6 60.86±1.71
45 73.6 71.3 72.3 72.4±1.15
60 78.8 79.2 82.4 81.1±1.9
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In-vitro drug release of co-precipitation 1:2 in pH 2.0
Time (min)
Fig . 44
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Zero order release of co-precipitation 1:2 in pH 2.0 
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Fig . 45
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Table 20:  In-vitro drug release of physical mixture 1:4 in pH 2.0
Time
(min)
Trial 1 Trial 2 Trial 3 Cumulative %
drug release
5 21.9 20.6 22.9 21.8± 1.15
10 27.9 26.6 28.5 27.6±0.97
20 35.4 37.8 38.6 37.2±1.63
30 57.4 56.9 59.3 57.8±1.26
72
45 62.7 61.9 64.8 63.13±1.49
60 68.5 67.5 69.5 68.5±1.0
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In-vitro drug release  of  physical mixture   1:4 in pH 2.0
Time (min)
Fig . 47 
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Zero order release of  physical mixture 1:4 in pH 2.0
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Fig . 48 
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Table 21:  In-vitro drug release of co-precipitation 1:4 in pH 2.0
Time
(min)
Trial 1 Trial 2 Trial 3 Cumulative %
drug release
5 37.1 35.3 38.5 36.9±1.6
10 45.9 47.2 48.7 47.2±1.4
20 58.4 56.9 53.6 56.3±2.4
30 69.2 65.5 67.4 67.3±2.4
45 74.3 76.9 78.3 76.5±2.03
60 83.8 84.3 81.5 83.2±1.49
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In-vitro drug release of co-precipitation1:4 in pH  2.0
Time (min)
Fig . 50
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Zero order release of co-precipitation1:4 in pH  2.0
Time (min)
Fig . 51 
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Table 22:  In-vitro drug release of Itraconazole in pH 3.0
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Time
(min)
Trial 1 Trial 2 Trial 3 Cumulative %
drug release
5 18.6 15.8 19.7 18.0±2.01
10 22.6 20.7 24.3 22.5±1.8
20 32.3 35.1 33.6 33.6±1.4
30 37.8 36.4 38.2 37.4±0.9
45 43.6 41.9 44.6 43.3±1.3
60 44.5 46.7 48.1 46.43±1.8
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In-vitro drug release of  Itraconazole in pH 3.0
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Zero order release of  Itraconazole in pH 3.0
Time (min)
 Fig. 54 
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Table 23:  In-vitro drug release of physical mixture 1:2 in pH 3.0
Time
(min)
Trial 1 Trial 2 Trial 3 Cumulative %
drug release
5 15.3 18.9 16.8 17.0±1.8
10 26.9 25.2 24.6 25.5±1.1
20 35.4 36.0 34.9 34.4±o.5
30 47.7 45.5 46.7 46.6±1.2
45 53.5 56.2 54.8 54.8±1.3
77
60 64.2 62.4 62.3 62.9±1.0
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In-vitro drug release of  physical mixture  1: 2 in pH 3.0
Time (min)
 Fig : 56 
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Zero order release of physical mixture 1:2 in pH 3.0
Time (min)
Fig . 57
C
u
m
u
la
tiv
e
 
%
 
 
dr
u
g 
re
le
a
s
e
 
0 10 20 30 40 50 60 70
0
0.5
1
1.5
2
2.5
f(x) =  - 0.01x + 1.96
R² = 0.98
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Table 24:  In-vitro drug release of Co- precipitation 1:2 in pH 3.0
Time
(min)
Trial 1 Trial 2 Trial 3 Cumulative %
drug release
5 30.6 32.4 31.6 31.5 ±0.9
10 36.2 37.8 36.9 36.9 ±0.8
20 44.5 43.2 42.8 43.5 ±0.85
30 51.9 50.7 52.4 51.6 ±0.87
45 68.4 69.4 67.5 68.4 ±1.0
60 79.3 78.8 77.9 78.5 ±0.72
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In-vitro drug release of  co-precipitate 1:2 in pH 3.0
Time (min)
Fig : 59
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f(x) = 1.09x + 17.79
R² = 0.88
Zero order release  of co-precipitate  1:2 in pH 3.0
Time (min)
Fig : 60
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Table 25: In-vitro drug release of physical mixture 1:4 in pH 3.0
Time (min) Trial 1 Trial 2 Trial 3 Cumulative %
drug release
5 30.1 28.6 29.7 29.46±0.77
10 34.2 32.4 33.8 33.4±0.94
20 41.6 43.1 42.4 42,3±0.75
30 51.7 52.1 53.5 52.34±0.94
45 63.4 64.7 62.8 63.43±0.97
60 69.8 71.4 70.3 70.5±0.81
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Fig : 62
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Zero order release of physical mixture 1:4 in pH 3.0
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Table 26:  In-vitro drug release of co-precipitation 1:4 in pH 3.0
Time
(min)
Trial 1 Trial 2 Trial 3 Cumulative %
drug release
5 37.1 35.3 38.5 36.9±1.6
10 45.9 47.2 48.7 47.2±1.4
20 58.4 56.9 53.6 56.3±2.4
30 69.2 65.5 67.4 67.3±2.4
45 74.3 76.9 78.3 76.5±2.03
60 83.8 84.3 81.5 83.2±1.49
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In-vitro drug release of co-precipitate 1:4 in pH  3.0
Time (min)
Fig : 65
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R² = 0.79
Zero order release of co-precipitate1:4 in pH  3.0
Time (min)
Fig : 66 
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Table 27: In-vitro drug release of Itraconazole in pH 4.0
Time
(min)
Trial 1 Trial 2 Trial 3 Cumulative %
drug release
5 19.4 23.1 21.9 21.46±1.8
10 28.5 31.6 29.0 29.7±1.6
20 37.4 39.8 35.9 37.7±1.9
30 47.3 44.7 46.6 46.2±1.3
45 51.6 53.6 52.1 52.4±1.04
60 59.4 62.4 60.81 60.8±1.5
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Fig : 68
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Zero order release of  Itraconazole in pH 4.0
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Fig : 69
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Table 28: In-vitro drug release of physical mixture in 1:2 in pH 4.0
84
Time
(min)
Trial 1 Trial 2 Trial 3 Cumulative %
drug release
5 33.8 32.4 31.2 32.4±1.2
10 39.7 38.6 41.3 39.8±1.4
20 48.5 44.9 46.6 46.6±1.8
30 59.6 58.2 62.1 59.9±1.9
45 67.4 64.0 66.5 65.9±1.7
60 74.6 71.8 75.9 74.1±1.4
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In-vitro drug release of  physical mixture 1:2 in pH 4.0
Time (min)
Fig : 71
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Zero order release of physical mixture 1:2 in pH 4.0
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 Fig : 72 
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First order release of physical mixture 1:2 in pH 4.0
Time (min)
Fig : 73
C
u
m
u
la
tiv
e
 
%
 
dr
u
g 
re
m
a
in
in
g
Table 29: In-vitro drug release of co-precipitation1:2 in pH 4.0
Time
(min)
Absorbanc
e (nm)
Concentration
(µg/ml)
Amount of
drug
release
Cumulative
% drug
release
5 40.4 38.6 41.5 40.16±1.4
10 1.451.7 54.3 52.9 52.96±1.3
20 66.3 67.9 65.8 66.6±1.0
30 69.6 71.4 72.1 71.0±1.2
45 74.5 78.5 76.3 76.4±2.0
60 79.9 83.5 84.3 82.5±2.3
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Fig : 75 
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Table: 30 In-vitro drug release of physical mixture 1:4 in pH 1.2
87
Time
(min)
Trial 1 Trial 2 Trial 3 Cumulative %
drug release
5 34.5 31.7 30.6 35.2±2.0
10 42.9 5.8 43.9 44.2±1.4
20 54.2 52.4 55.7 54.1±1.6
30 65.8 62.5 68.3 65.5±2.9
45 71.5 70.8 73.6 71.9±1.4
60 76.8 78.3 75.2 76.7±1.5
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In-vitro drug release of physical mixture   1:4 in pH 4.0
Time (min)
Fig :77
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Table 31:  In-vitro drug release of Co-precipitation 1:4 in pH 4.0
Time
(min)
Trial 1 Trial 2 Trial 3 Cumulative %
drug release
5 33.6 32.6 35.4 33.8±1.4
10 43.8 44.6 42.6 43.6±1.0
20 51.4 53.8 54.4 53.2±1.5
30 66.4 62.4 65.8 64.8±2.1
45 71.8 73.8 70.5 72.0±1.6
60 85.9 86.2 88.3 86.8±1.308
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Table 32: Comparative In-vitro dissolution of Itraconazole in different pH buffers
Time
Cumulative % drug release of Itraconazole
pH 1.2 pH 2.0 pH 3.0 pH 4.0
5 12.93±0.41 13.9±1.3 18.0±2.01 21.46±1.8
10 15.63±0.75 21.8±1.4 22.5±1.8 29.7±1.6
20 22.733±0.8 27.5±1.3 33.6±1.4 37.7±1.9
90
30 26.03±0.83 35.6±1.1 37.4±0.9 46.2±1.3
45 31.563±0.8 39.1±1.6 43.3±1.3 52.4±1.04
60 35.063±0.89 42.3±1.2 46.43±1.8 60.8±1.5
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Table 33: Comparative In-vitro dissolution of ITC physical mixture in Different pH
buffers
Time
Cumulative % drug release of  physical mixture 1:2
pH 1.2 pH 2.0 pH 3.0 pH 4.0
5 26.4±0.81 23.2±1.6 17.0±1.8 32.4±1.2
10 29.48±0.87 28.9±1.1 25.5±1.1 39.8±1.4
91
20 31.6±0.86 36.7±1.8 34.4±o.5 46.6±1.8
30 36.33±0.94 45.2±1.4 46.6±1.2 59.9±1.9
45 47.36±0.66 56.4±1.9 54.8±1.3 65.9±1.7
60 57.3±0.61 59.6±2.8 62.9±1.0 74.1±1.4
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  Table 34: Comparative In-vitro dissolution of ITC Co- precipitate in different pH
buffers
Time
Cumulative % drug release of co-precipitation 1:2
pH 1.2 pH 2.0 pH 3.0 pH 4.0
5 24.16±1.49 32.2±1.8 31.5 ±0.9 40.16±1.4
10 36.6±1.6 38.8±1.7 36.9 ±0.8 52.96±1.3
20 45.2±2.4 45.53±1.30 43.5 ±0.85 66.6±1.0
30 56.1±1.2 60.86±1.71 51.6 ±0.87 71.0±1.2
45 67.3±1.6 72.4±1.15 68.4 ±1.0 76.4±2.0
60 73.2±2.7 81.1±1.9 78.5 ±0.72 82.5±2.3
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Table 35: Comparative In-vitro dissolution of ITC physical mixture 1:4 in different
pH buffers
Time
Cumulative % drug release of physical mixture 1:4
pH 1.2 pH 2.0 pH 3.0 pH 4.0
5 24.8±1.4 21.8± 1.15 29.46±0.77 35.2±2.0
10 33.6±1.2 27.6±0.97 33.4±0.94 44.2±1.4
20 41.5±1.9 37.2±1.63 42,3±0.75 54.1±1.6
30 55.0±1.3 57.8±1.26 52.34±0.94 65.5±2.9
45 59.0±1.5 63.13±1.49 63.43±0.97 71.9±1.4
60 66.9±1.2 68.5±1.0 70.5±0.81 76.7±1.5
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Table 36: Comparative In-vitro dissolution of ITC co-precipitation 1:4 in different
pH buffers
Time
Cumulative % drug release of co-precipitation
1: 4
pH 1.2 pH 2.0 pH 3.0 pH4.0
5 30.1±1.57 36.9±1.6 34.5±0.70 33.8±1.4
10 37.4±1.99 47.2±1.4 44.1±0.76 43.6±1.0
20 50.93±1.38 56.3±2.4 52.7±0.95 53.2±1.5
30 63.9±1.6 67.3±2.4 63.5±0.65 64.8±2.1
45 69.1±1.99 76.5±2.03 79.0±0.80 72.0±1.6
60 82.7±1.8 83.2±1.49 84.5±0.77 86.8±1.308
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Table 37: Comparative In-vitro dissolution study of different formulations in pH
(1.2) buffer
Time ITC
Cumulative % drug release  in pH 1.2
PM 1:2 CO-PPT1:2 PM 1:4 CO-PPT 1:4
5 12.93±0.41 26.4±0.81 32.2±1.8 24.8±1.4 30.1±1.57
10 15.63±0.75 29.48±0.8
7
38.8±1.7 33.6±1.2 37.4±1.99
20 22.733±0.8 31.6±0.86 45.2±2.4 41.5±1.9 50.93±1.38
30 26.03±0.83 36.33±0.9
4
56.1±1.2 55.0±1.3 63.9±1.6
45 31.563±0.8 47.36±0.6
6
67.3±1.6 59.0±1.5 69.1±1.99
96
60 35.063±0.8
9
57.3±0.61 73.2±2.7 66.9±1.2 82.7±1.8
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Table 38:  Comparative In-vitro dissolution of different formulations in pH (2.0)
buffer
Time ITC
Cumulative % drug release in pH  2.0
PM 1:2 CO-PPT1:2 PM 1:4 CO-PPT 1:4
5 13.9±1.3 23.2±1.6 24.16±1.49 21.8± 1.15 36.9±1.6
10 21.8±1.4 28.9±1.1 36.6±1.6 27.6±0.97 47.2±1.4
20 27.5±1.3 36.7±1.8 45.53±1.30 37.2±1.63 56.3±2.4
30 35.6±1.1 45.2±1.4 60.86±1.71 57.8±1.26 67.3±2.4
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45 39.1±1.6 56.4±1.9 72.4±1.15 63.13±1.49 76.5±2.03
60 42.3±1.2 59.6±2.8 81.1±1.9 68.5±1.0 83.2±1.49
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Table 39: Comparative In-vitro dissolution of different formulations in pH (3.0)
buffer
Time ITC
Cumulative % drug release in  pH 3.0
PM 1:2 CO-PPT1:2 PM 1:4 CO-PPT 1:4
5 18.0±2.01 17.0±1.8 31.5 ±0.9 29.46±0.77 34.5±0.70
10 22.5±1.8 25.5±1.1 36.9 ±0.8 33.4±0.94 44.1±0.76
20 33.6±1.4 34.4±o.5 43.5 ±0.85 42,3±0.75 52.7±0.95
30 37.4±0.9 46.6±1.2 51.6 ±0.87 52.34±0.94 63.5±0.65
98
45 43.3±1.3 54.8±1.3 68.4 ±1.0 63.43±0.97 79.0±0.80
60 46.43±1.8 62.9±1.0 78.5 ±0.72 70.5±0.81 84.5±0.77
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Table 40: Comparative In-vitro dissolution of different formulations in pH (4.0)
buffers
Time ITC
Cumulative % drug release in pH 4.0
PM 1:2 CO-
PPT1:2
PM 1:4 CO-PPT
1:4
5 21.46±1.8 32.4±1.2 40.16±1.4 35.2±2.0 33.8±1.4
10 29.7±1.6 39.8±1.4 52.96±1.3 44.2±1.4 43.6±1.0
20 37.7±1.9 46.6±1.8 66.6±1.0 54.1±1.6 53.2±1.5
99
30 46.2±1.3 59.9±1.9 71.0±1.2 65.5±2.9 64.8±2.1
45 52.4±1.04 65.9±1.7 76.4±2.0 71.9±1.4 72.0±1.6
60 60.8±1.5 74.1±1.4 82.5±2.3 76.7±1.5 86.8±1.308
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8.5  In-vivo bioavailability of pure Itraconazole Physical mixture and
co-precipitation 1:4 ratio.
Pure Itraconazole Fig. 92
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8.5 Comparative In-vivo pharmacokinetic study 
Table 41: Comparative study of Pharmacokinetic parameters.
PARAMETERS PURE±SEM PHY MIX±SEM CO-PPT±SEM P- value 
KE 0.0176±0.00318 0.0286±0.00088 0.132±0.0023
***P<0.00
1
Ka 0.031±0.002728 0.0506±0.00504 0.233±0.0095
***P<0.01
t1/2 22.4±2.095 14.16±1.462 2.96±0.1202
***P<0.00
1
Vd 39.2±3.3 42.19±3.57 45.4±0.4583
N.S
Cmax 0.176±0.0233 0.32±0.01732 0.42±0.02906
***P<0.00
1
Tmax 2.746±0.02728 2.32±0.0933 1.67±0.0895
***P<0.01
AUC0-8 4.57±0.2083 6.72±0.2800 9.7±0.9528
***P<0.00
1
AUC0-∞ 9.53±0.3756 10.4±0.3215 15.6±1.365
***P<0.00
1
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Fig .93 GRAPHICAL REPRESENTATIONS OF PHARMACOKINETIC PARAMETERS
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9. RESULTS AND DISCUSSION
FTIR spectra of all formulations 
The FTIR spectra for pure Itraconazole, pure β- cyclodextrin, physical mixture,
and co-precipitate of Itraconazole and β- cyclodextrin (1:2 and 1:4) are shown in table 6
figure  3-8.  The  characteristic  FTIR  spectra  of  Itraconazole  and  β-  cyclodextrin  were
observed. In  physical mixture’s indicating no complex formation or interaction between
Itraconazole and β- cyclodextrin, physical mixture, however in co-precipitate the  spectra
of dimethylalkane and  α, β, 5- member ring were absent this shows complex formation
between Itraconazole and β- cyclo dextrin .
The results  of  the FTIR spectra  shows that  an inclusion complex was formed
between  Itraconazole  and  β-  cyclo  dextrin  by  co-precipitation  method  and  physical
mixture of Itraconazole and β- cyclo dextrin did not bring about interactions between the
drug and β- cyclo dextrin. The results of FTIR spectra shows that an inclusion complex
was formed between Itraconazole and β-  cyclodextrin by co-precipitation method and
physical  mixing  of  Itraconazole  and  β-  cyclodextrin  did  not  bring  about  interaction
between the drug and β- cyclodextrin.
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Differential scanning calorimetry (DSC)
DSC curves for pure Itraconazole pure β-cyclodextrin, physical mixture and co-
precipitate are (1:2 and 1:4) ratios of Itraconazole and β-cyclodextrin are shown a figure
9-14 Pure Itraconazole shows a sharp melting endoderm at 168.9°c. Pure β-cyclodextrin
showed two peaks a broad endothermal effect ranging between 50- 100°c corresponding
to  dehydration  of  β-cyclodextrin  and  second  at  245°c  characteristic  of  pure  β-
cyclodextrin. DSC curves of the physical  mixture for both drug: β-cyclodextrin ratios
(1:2 and1:4) consists  of thermal profiles of drug and cyclodextrin with no significant
changes  in  peaks  showing no drug cyclodextrin  interactions.  DSC curves  for  the co-
precipitate showed slight broadening of endothermal peak for β-cyclodextrin at 245°c and
more  broadening  of  the  endothermal  peak  for  β-cyclodextrin  between  50  -  150°c
indicative  of  drug – cyclodextrin  interaction.  The endothermal peak corresponding to
pure β-cyclodextrin was more broader in the co-precipitate with 1:4 (dug: cyclodextrin)
compared  to  that  for  1:2  (dug:  cyclodextrin)  ratio.  These  findings  suggest  higher
inclusion yield for the co-precipitate having 1:4 (drug: β-cyclodextrin).
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Phase solubility
The effect of β-cyclodextrin in different concentrations on the solubility of the
Itraconazole was examined and the results are shown in the table and figures. 7 and 15-18
respectively.  The  solubility  of  Itraconazole  decreased  as  pH increases  from 1.2-  4.0.
Itraconazole being weakly basic in character becomes more un-ionised in higher pHs.
Which  is  supportive  of  earlier  finding  that  absorption  is  enhanced  by  concurrent
administration of food possibly due to increase in gastric pH by the effect of food and
thus establishing the unionized form are more absorbable. Solubility of Itraconazole as
increased propionately with increase in the con of β-cyclodextrin in pH 1.2 medium and
this increase was reduced as pH increased.
The increase in solubility by the effect of cyclodextrin may be that structure of
cyclodextrin is analogous to a truncated cone with a hydrophobic interior and hydrophilic
exterior,  This  allows  the  mode  of  encapsulatution  of  hydrophobic  portions  of  gust
molecules thus shielding them from the polar forces of aqueous solutions. The increased
solubility  of  Itraconazole  by the  effect  of  β-cyclodextrins  may also  be  through  non-
inclusion  complex  formation,  on  finding  is  in  consistent  with  earlier  report  that
cyclodextrin  complexes  can  self  associate  to  form  aggregate  through  non-  inclusion
complex by micelle like structure, which also effectively solubilize poorly water soluble
drugs.18
Previously it has been reported from the phase solubility study 2-oH- propyl β-
cyclodextrin improves solubility of Itraconazole in aqueous solution.20 The results of the
phase solubility study clearly suggest that solubility of Itraconazole though improved by
β- cyclodextrins, it decreases in higher gastric pH condition which is normally seen after
taking food.
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In-vitro dissolution
Dissolution  profile  of  pure  Itraconazole,  physical  mixture  and  co-precipitate,
Itraconazole β-cyclodextrin, (1:2 and1:4) is shown i n the tables 8- and figure 15-86. The
% drug release increased over time and reached above 35% in pH1.2 medium and as the
pH of the medium increased the % drug release also increased thus showing the effect of
pH on  the  dissolution  of  Itraconazole  as  it  has  been  reported  earlier6 absorption  of
Itraconazole is  enhanced by the concurrent  administration of food and the gastric  pH
increase  in  presence  of  food  and  so  my  be  the  effect  of  enhanced  dissolution  of
Itraconazole in higher acidic pHs as observed in the present study. Dissolution amounts
were more from physical mixture as compare to pure Itraconazole and the dissolution
amounts of physical mixture of 1:4 (drug: β-CD) were more than that of physical mixture
of 1:2 (drug: β-CD) ratios. These findings are in consisting with our findings in phase
solubility study where the solubility of Itraconazole increased as concentration of β-CD
increase so the higher dissolution amount with higher con of β-CD is due to enhanced
solubility of Itraconazole by the effect of β-CD. The solid state of drug was not effected
in the  physical  mixture  as  observed in  the thermogram and  as  such  the influence  of
physical state of drug on the dissolution of Itraconazole is less likely. Dissolution amount
of co-precipitate was higher than that  of pure drug as well  as physical  mixtures. Co-
precipitate1:4 (drug: β-CD) ratio showed higher dissolution amounts as compared to that
of co-precipitate 1:2 (drug: β-CD) ratio as evident from DSC. The endothermic peak of β-
CD was more broader in co-precipitate 1:4(drug : β-CD) than in co-precipitate 1:2 (drug:
β-CD) as the evident from the DSC thermo gram, suggesting more inclusion complex
formation with higher concentrations of β-CD’s and therefore higher dissolution amounts
with higher con of β-CD.
 Comparison of   dissolution profile of  physical  mixture and co-precipitate at
varying acidic pH’s shows maximum dissolution amounts from co-precipitate 1:4 (drug:
β-CD) as compared to other formulation and dissolution amounts of co-precipitate of 1:4
(drug :β-CD) increased as the pH increased in the same pattern of increased dissolution
amounts  of   physical  mixture and co-precipitate1:2 (drug:  β-CD) ratio  was observed.
Physical  mixture  1:4  (drug:  β-CD)  showed  higher  dissolution  amount  compare  to
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physical  mixture  1:2  (drug:  β-CD).  Similarly  co-precipitate1:4  (drug:  β-CD)  showed
higher  dissolution  amount  compared  to  co-precipitate  1:2  (drug:  β-CD).  The  highest
dissolution of Itraconazole from co-precipitate 1:4 (drug: β-CD) sis due to more inclusion
complex  formation  observed  in  the  DSC  thermo  gram.  β  -cyclodextrin  in  increased
concentrations increases the solubility as well as dissolution of Itraconazole from both
physical  mixture and co-precipitation. The increased dissolution of Itraconazole either
from the physical  mixture or  from the co-precipitate  in higher  acidic ph suggest  that
absorption of  Itraconazole is enhanced by β-CD, and this absorption is further influenced
by improved dissolution of Itraconazole at  higher acidic pH from physical mixture as
well as co-precipitate.
The results of dissolution study proposes that β-CD can improve the dissolution,
absorption and  bioavailability of Itraconazole and these factors are influenced by pH of
acidic environment of the stomach.
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In-vivo pharmacokinetics
Based on dissolution profile of the formulations the physical mixture 1:4 (drug: β-
CD) and co-precipitate 1:4 (drug: β-CD) were selected as the best formulation and the in-
vivo pharmacokinetics of these formulations were studied. Plasma con of Itraconazole,
physical mixture and co-precipitate after oral admin are shown in  table 40 and figure 91-
98. Ke, Ka, Cmax, AUC0-8, and  AUC 0-∞,  showed higher values from physical mixture
and co-precipitate  as compared to that of pure Itraconazole  and these values were higher
with co-precipitation  as compared to physical mixture that showing the formulation of
inclusion  complex  in  the  co-precipitate  resulting  in  improved  dissolution  and
pharmacokinetics of co-precipitate. The t1/2 and Tmax of co-precipitate were significantly
lower and that of physical mixture as well as pure Itraconazole, thus further supporting
the  enhanced  absorption  of  Itraconazole  from  the  co-precipitate  through  inclusion
complex formation.
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10.  SUMMARY AND CONCLUSION
 Co-precipitation of 1:4 (drug: β-CD) showed higher dissolution as compared to
co-precipitation  1:2 (drug: β-CD) physical mixture (1:2,1:4) ( drug: β-CD) and
pure Itraconazole
 Dissolution amounts of co-precipitate increased as the pH of acidic environment
increased.
  Solubility of Itraconazole was improved with higher concentrations of  β-CD.
 Inclusion complex formation was detected in co-precipite’s as observed in the
DSC  thermograms.   Physical  mixture  did  not  show  interaction  between
Itraconazole and  β-CD as  supported by the  results  of  FTIR spectra  and  DSC
analysis.
 The enhanced dissolution of Itraconazole from co-precipitate of 1:4 (drug: β-CD)
was reflected in improved pharmacokinetics of co-precipitate.
 The  results  of  the  study  proposes  that  the  dissolution  and  bio-availability  of
Itraconazole can be improved by using β- cyclodextrin, how ever bioavailability
of Itraconazole can be influenced by the pH conditions of the gastric environment
as evident from dissolution study.
 Further studies are warranted to examine the effect of food on the bio availability
of Itraconazole-β-cyclodextrin complex.
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